Recent Updates
Recently added Catalysts

Tibulizumab Dose A

Phase 2

Hidradenitis Suppurativa (HS) | Monoclonal antibody | Dermatology |Zura Bio Limited|Last Updated: Jun 30, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials1
Total Enrollment225
FDA Designations
No designations recorded
Clinical trial landscape

Tibulizumab Dose A · 1 trial · 1 indication

Phase 2 1
NCT06993610Tibulizumab Skin Healing and Inflammation Evaluation for Lasting DefenseHidradenitis Suppurativa (HS)
ACTIVE NOT_RECRUITING225 Analytics
PHASE2ACTIVE NOT_RECRUITING
Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense
Hidradenitis Suppurativa (HS)
NCT06993610225
Unlock trial analytics
Study Endpoints
Primary Endpoints
[Period 1] Percent change from baseline in abscess and inflammatory nodule (AN) count at 16 weeks
Week 16

AN count is calculated based on the sum of the abscesses and inflammatory nodules across different anatomical areas

Secondary Endpoints
[Period 1] Achieving HiSCR50 at Week 16
Week 16
[Period 1] Achieving HiSCR75 at Week 16
Week 16
[Period 1] Absolute change from baseline in Dermatology Life Quality Index (DLQI) score at Week 16
Week 16
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingTRIPLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Tibulizumab Dose AEXPERIMENTALSubcutaneous injection
Tibulizumab Dose BEXPERIMENTALSubcutaneous injection
PlaceboPLACEBO_COMPARATORSubcutaneous injection
Interventions
NameTypeDescription
Tibulizumab Dose ABIOLOGICALAnti BAFF/IL-17 antibody. ZB-106
Tibulizumab Dose BBIOLOGICALAnti BAFF/IL-17 antibody. ZB-106
PlaceboOTHERZB-106 Placebo
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to 70 Years
SexALL
Healthy VolunteersNo
Study Sites61

Inclusion Criteria: * Male or female, 18 to 70 years of age * ≥6-month history of Hidradenitis suppurativa (HS) * Total AN (abscess and inflammatory nodule) count ≥5 * HS lesions in ≥2 distinct anatomical areas, at least one of which is Hurley Stage II or III Exclusion Criteria: * Draining tunnel...

Countries:United StatesCanadaGermanyHungaryPolandSpain
Unlock Eligibility Criteria
Competitive Landscape -Hidradenitis Suppurativa 38 trials (matched to "Hidradenitis Suppurativa (HS)")
CompanyTickerTrialsLead PhaseDrugs
AbbVie, Inc.ABBV5PHASE3Lutikizumab
Incyte CorporationINCY6PHASE3Povorcitinib
Novartis AG Sponsored ADRNVS12PHASE3secukinumab
MoonLake Immunotherapeutics Class AMLTX2PHASE3Sonelokimab
Sanofi SA Sponsored ADRSNY2PHASE2Brivekimig
Eli Lilly and CompanyLLY1PHASE2Eltrekibart
Pfizer Inc.PFE1PHASE2Ritlecitinib
Merck & Co., Inc.MRK1PHASE2Tulisokibart
Takeda Pharmaceutical Co. Ltd. Sponsored ADRTAK1PHASE2Zasocitinib
Zura Bio Limited Class AZURA1PHASE2Tibulizumab Dose A, Tibulizumab Dose B
Sonoma Pharmaceuticals, Inc.SNOA2PHASE1SBT777101
Evommune, Inc.EVMN1EARLY_PHASE1EVO101
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
MEDIUMJun 30, 2026NCT06993610Status: RECRUITING → ACTIVE_NOT_RECRUITING
MEDIUMJun 30, 2026NCT06993610Status: RECRUITING → ACTIVE_NOT_RECRUITING
MEDIUMJun 30, 2026NCT06993610Status: RECRUITING → ACTIVE_NOT_RECRUITING
LOWMay 26, 2026NCT06993610primaryCompletionDate: changed
LOWMay 24, 2026NCT06993610studyFirstPostDate: changed